Precision Medicine. Applied.

Leveraging the power of pharmacogenomics (PGx) to provide innovative and cost-effective precision medicine

Find out how you can control costs while improving the health and satisfaction of your members.

Pharmacogenomics

Just as there are known drug-drug interactions, there are also known drug-gene interactions. Pharmacogenomics is the study of how a person’s genes affect their response to specific medications. It is a type of precision medicine.

Scientists have found that specific areas of our DNA can predict whether certain medications will be effective or if they are likely to cause adverse drug reactions.

Currently, the FDA includes pharmacogenomic warnings on the labels of more than 200 medications.* A one-time saliva test lets doctors know whether a patient has specific genetic variants. This knowledge can influence dosing and the choice of medication. It can also alert physicians to avoid specific drugs.

*Table of Pharmacogenomic Biomarkers in Drug Labeling. US Food & Drug Administration website. Updated Feb 8, 2018. Accessed April 6, 2018. Available at: https://www.fda.gov/Drugs/ScienceResearch/ucm572698.htm

Drug Facts

Did you know?

Applied Precision Medicine
For Healthy Outcomes.

Coriell Life Sciences offers a comprehensive turnkey solution that enables organizations to offer one-time pharmacogenomic screening to their members. We’ll take care of everything—from sending invitations to reporting results. You don’t have to do a thing.

Reduce Healthcare Costs

Reduce Healthcare Costs While Improving the Health and Satisfaction of Plan Members

Our proven methodology leverages the findings of the Coriell Institute and current FDA data to ensure your members are taking only those drugs that work for them. We’re confident you’ll realize an immediate decrease in your pharmaceutical spend. Our clients also realize subsequent reductions in adverse medication reactions, hospitalizations, emergency department visits, slip and falls, and hospital readmissions.

Our Personalized Medicine

A Turnkey Medication Management Serving a Range of Customers

  • Self-insured businesses
  • National, state and local government benefit providers
  • Healthcare payers
  • Capitated Providers
  • Accountable Care Organizations (ACOs)
  • Countries with single-payer health care
  • Single-payer systems
Pharmacogenics

How it Works

Step 01

Population Risk Assessment

The program begins with an analysis of your claims data, which we run through the Coriell Health Insight Portal (CHIP). Our algorithm can evaluate your population to determine potential risks, the number of people likely to benefit, and estimate your ROI.

For those organizations wishing to take a phased approach, we can begin with the subset of cohorts who would most benefit from PGx testing.

Step 02

Invitations Sent

CLS sends out invitations to your members, inviting them to participate in the new, voluntary benefit. This invitation is customizable and can accommodate your branding and language specific to your member population.

Step 03

Enrollment and Onboarding

The invitations provide your members with a phone number to an enrollment hotline as well as a link to an online enrollment site. Both sources also offer educational information and answers to FAQs.

As part of the enrollment process, we gather information on a member’s over-the-counter (OTC) medications, vitamins and supplements, and lifestyle, all of which aid in their medication analysis.

Step 04

DNA Collection Kits Sent

After enrolling, members receive a DNA collection kit with your branding. They simply spit into the tube provided and mail it to our lab in the postage-paid package.

Step 05

Laboratory Analysis

Our network of laboratories conduct the pharmacogenetics (PGx) analysis on the members’ DNA samples. This data is then sent to Coriell Life Sciences.

Step 06

Genetic Interpretation

The PGx data is run through the proprietary CLS algorithms. These algorithms arebased on extensive scientific research and clinical outcomes data from the Coriell Institute. The data driving these algorithms are regularly updated to reflect current research findings, new drug approvals, and current FDA advisories.

Step 07

Comprehensive Reporting

Based on the genetic interpretation, CLS generates a comprehensive report that takes into account a member’s:

  • Pharmacogenomics
  • Prescription and over-the-counter medications
  • Supplements
  • Health conditions
  • Age
  • Lifestyle (foods, drinks, smoking, etc)

The report includes:

  • Pharmacogenomic alerts
  • Potential drug-drug interactions
  • Information from FDA black box warnings

The detailed report is presented in both printed and interactive form.

Step 08

Expert Pharmacist Review and Recommendations

A pharmacy review team—yours or ours uses the real-time decision support tool to analyze appropriate substitute medications and pricing. Clear clinical recommendations are generated in the form of a Medication Action Plan (MAP).

Step 09

Physician Outreach

Pharmacists reach out to members’ designated physicians to provide clear, medically-relevant, and clinically-actionable recommendations. Physicians do not need to pore through the report; nor are they responsible for any interpretation.

Step 10

Prescription Modifications

Physicians, in concert with their patients, can elect to act on the MAP recommendations by “deprescribing” problematic medications, and switching to safer and more effective medications.

Step 11

Ongoing Savings Realization

Organizations and their members realize immediate savings through deprescribing of unnecessary and harmful medications.

Longer-term and ongoing savings are realized due to reductions in:

  • adverse drug events
  • slip and falls
  • hospitalizations
  • emergency room visits
  • hospital readmissions

Our real-time dashboard enables organizations to track metrics based on your specific goals and KPIs.

Enterprise PGx

Precision Medicine in Action

Teachers' Group Retirement Plan

Teachers’ Group Retirement Plan

Read More

Contact Us

Let's Get Started

Do you want to control your healthcare spend while improving the health and satisfaction of your members? Contact us to find out how much you could save.

Call (888) 415-7834 – or let us know below how we can reach you, and we’ll be in touch.






* required

Coriell Addresses FDA Concerns on Pharmacogenomics

November 1, 2018

Earlier today, the Food and Drug Administration (FDA) released a statement warning consumers about the potential risks of using genetic testing services to provide unproven guidance on medication response.

This warning comes in association with an announcement that the FDA has approved an application by the consumer genetic testing company 23andMe to provide pharmacogenomics (PGx) results through its mail order service. 23andMe will be required to inform consumers that their test should not be used for medical treatment and that any results need to be confirmed by additional clinical pharmacogenomic testing.

We at Coriell Life Sciences support the position of the FDA and believe they have acted in the best interest of the public by raising the awareness of the potential risks involved in providing seemingly clinical advice that has not achieved the level of scientific rigor and review required to ensure patient safety. Genetic testing for medication response is a relatively new science, and while the evidence is extremely strong for some genes and correlating drugs, many other correlations are still emerging. It is important that consumers are made aware of these facts, and that healthcare providers exercise diligence in choosing a partner for important new pharmacogenomics information.

Coriell Life Sciences’ own work in the science of pharmacogenomics began with the 66-year-old Coriell Institute for Medical Research where the late Dr. Michael Christman pioneered a 10-year research study aimed at determining the best way to deliver actionable genetic guidance in the clinic. The study has resulted in dozens of publications and collaborations including the peer-reviewed methodology for the scoring of evidence known as PhAESIS. This approach, which has been widely applauded as being both reasonable and rigorous, ensures that the results of genetic testing are not driven by commercial aims, but rather by strong, independent scientific review.

Moreover, we firmly believe that PGx testing alone is not sufficient to make clinical decisions on medication treatment. A patient’s response to medications is influenced by many factors, including drug interactions, lifestyle factors, and more. Genetics is an important but singular concern that should be addressed in concert with the total patient health, by a medical professional, to ultimately arrive at a treatment plan tailored to that individual’s unique circumstances. Our bioinformatics platform, GeneDose Live, and our Enterprise PGx program rely on the combination of rigorously reviewed scientific evidence, data analytics, expert pharmacy review, and collaboration with the patient’s own doctor. The results have been clear. Implemented in this way, as part of a holistic clinical decision support process, pharmacogenomics provides better patient outcomes and reduces the overall cost of care.

Scott Megill
President & CEO
Coriell Life Sciences
info@coriell.com

Coriell Addresses FDA Concerns on Pharmacogenomics

November 1, 2018

Earlier today, the Food and Drug Administration (FDA) released a statement warning consumers about the potential risks of using genetic testing services to provide unproven guidance on medication response.

This warning comes in association with an announcement that the FDA has approved an application by the consumer genetic testing company 23andMe to provide pharmacogenomics (PGx) results through its mail order service. 23andMe will be required to inform consumers that their test should not be used for medical treatment and that any results need to be confirmed by additional clinical pharmacogenomic testing.

We at Coriell Life Sciences support the position of the FDA and believe they have acted in the best interest of the public by raising the awareness of the potential risks involved in providing seemingly clinical advice that has not achieved the level of scientific rigor and review required to ensure patient safety. Genetic testing for medication response is a relatively new science, and while the evidence is extremely strong for some genes and correlating drugs, many other correlations are still emerging. It is important that consumers are made aware of these facts, and that healthcare providers exercise diligence in choosing a partner for important new pharmacogenomics information.

Coriell Life Sciences’ own work in the science of pharmacogenomics began with the 66-year-old Coriell Institute for Medical Research where the late Dr. Michael Christman pioneered a 10-year research study aimed at determining the best way to deliver actionable genetic guidance in the clinic. The study has resulted in dozens of publications and collaborations including the peer-reviewed methodology for the scoring of evidence known as PhAESIS. This approach, which has been widely applauded as being both reasonable and rigorous, ensures that the results of genetic testing are not driven by commercial aims, but rather by strong, independent scientific review.

Moreover, we firmly believe that PGx testing alone is not sufficient to make clinical decisions on medication treatment. A patient’s response to medications is influenced by many factors, including drug interactions, lifestyle factors, and more. Genetics is an important but singular concern that should be addressed in concert with the total patient health, by a medical professional, to ultimately arrive at a treatment plan tailored to that individual’s unique circumstances. Our bioinformatics platform, GeneDose Live, and our Enterprise PGx program rely on the combination of rigorously reviewed scientific evidence, data analytics, expert pharmacy review, and collaboration with the patient’s own doctor. The results have been clear. Implemented in this way, as part of a holistic clinical decision support process, pharmacogenomics provides better patient outcomes and reduces the overall cost of care.

Scott Megill
President & CEO
Coriell Life Sciences
info@coriell.com

Coriell Addresses FDA Concerns on Pharmacogenomics

November 1, 2018

Earlier today, the Food and Drug Administration (FDA) released a statement warning consumers about the potential risks of using genetic testing services to provide unproven guidance on medication response.

This warning comes in association with an announcement that the FDA has approved an application by the consumer genetic testing company 23andMe to provide pharmacogenomics (PGx) results through its mail order service. 23andMe will be required to inform consumers that their test should not be used for medical treatment and that any results need to be confirmed by additional clinical pharmacogenomic testing.

We at Coriell Life Sciences support the position of the FDA and believe they have acted in the best interest of the public by raising the awareness of the potential risks involved in providing seemingly clinical advice that has not achieved the level of scientific rigor and review required to ensure patient safety. Genetic testing for medication response is a relatively new science, and while the evidence is extremely strong for some genes and correlating drugs, many other correlations are still emerging. It is important that consumers are made aware of these facts, and that healthcare providers exercise diligence in choosing a partner for important new pharmacogenomics information.

Coriell Life Sciences’ own work in the science of pharmacogenomics began with the 66-year-old Coriell Institute for Medical Research where the late Dr. Michael Christman pioneered a 10-year research study aimed at determining the best way to deliver actionable genetic guidance in the clinic. The study has resulted in dozens of publications and collaborations including the peer-reviewed methodology for the scoring of evidence known as PhAESIS. This approach, which has been widely applauded as being both reasonable and rigorous, ensures that the results of genetic testing are not driven by commercial aims, but rather by strong, independent scientific review.

Moreover, we firmly believe that PGx testing alone is not sufficient to make clinical decisions on medication treatment. A patient’s response to medications is influenced by many factors, including drug interactions, lifestyle factors, and more. Genetics is an important but singular concern that should be addressed in concert with the total patient health, by a medical professional, to ultimately arrive at a treatment plan tailored to that individual’s unique circumstances. Our bioinformatics platform, GeneDose Live, and our Enterprise PGx program rely on the combination of rigorously reviewed scientific evidence, data analytics, expert pharmacy review, and collaboration with the patient’s own doctor. The results have been clear. Implemented in this way, as part of a holistic clinical decision support process, pharmacogenomics provides better patient outcomes and reduces the overall cost of care.

Scott Megill
President & CEO
Coriell Life Sciences
info@coriell.com